6-K 1 form6k_051425.htm 6-K Document


FORM 6-K


U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of May 2025

 Commission File Number: 001-38757
TAKEDA PHARMACEUTICAL COMPANY LIMITED
(Translation of registrant’s name into English)

1-1, Nihonbashi-Honcho 2-Chome
Chuo-ku, Tokyo 103-8668
Japan
(Address of principal executive offices)


Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F  ☒            Form 40-F  ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐


Information furnished on this form:
EXHIBIT



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Date: May 14, 2025By:/s/ Norimasa Takeda
Norimasa Takeda
Chief Accounting Officer and Corporate Controller


[Cover]
[Document Filed]Share Repurchase Report
[Applicable Law]Article 24-6, paragraph 1 of the Financial Instruments and Exchange Act of Japan
[Filed with]Director, Kanto Local Finance Bureau
[Filing Date]May 14, 2025
[Reporting period]From April 1, 2025 to April 30, 2025
[Company Name]Takeda Pharmaceutical Company Limited
[Title and Name of Representative]Christophe Weber, Representative Director, President & Chief Executive Officer
[Address of Head Office]1-1, Doshomachi 4-chome, Chuo-ku, Osaka
(The above address is the registered head office location and the ordinary business operations are conducted at the “Nearest Place of Contact”)
[Telephone Number]Not applicable
[Name of Contact Person]Not applicable
[Nearest Place of Contact]1-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo
(Global Headquarters)
[Telephone Number]+81-3-3278-2111 (Main telephone number)
[Name of Contact Person]Norimasa Takeda, Chief Accounting Officer & Corporate Controller, Global Finance
[Place for public inspection]Takeda Pharmaceutical Company Limited (Global Headquarters)
(1-1, Nihonbashi Honcho 2-chome, Chuo-ku, Tokyo)
Tokyo Stock Exchange, Inc.
(2-1, Nihonbashi Kabutocho, Chuo-ku, Tokyo)
Nagoya Stock Exchange, Inc.
(8-20, Sakae 3-chome, Naka-ku, Nagoya)
Fukuoka Stock Exchange
(14-2, Tenjin 2-chome, Chuo-ku, Fukuoka)
Sapporo Stock Exchange
(14-1, Minamiichijonishi 5-chome, Chuo-ku, Sapporo)

Class of Shares: Common Stock
1.Status of repurchase
(1)Status of repurchase pursuant to a resolution approved by a General Meeting of Shareholders
Not applicable
(2)Status of repurchase pursuant to a resolution approved by a meeting of the Board of Directors
As of April 30, 2025
Number of shares (shares)
Total repurchase
amount (JPY)
Status of the resolution of the Board of Directors (January 30, 2025)
(Period of repurchase: from February 17, 2025 to May 31, 2025)
28,500,000
100,000,000,000
Repurchases during this reporting month (Date of repurchase)
(Date)
April 3, 2025692,7003,107,893,200
April 4, 2025692,7003,088,441,400
April 7, 2025692,7003,114,681,300
April 8, 2025692,7003,095,066,200
April 9, 2025745,3003,138,038,100
April 10, 2025745,3003,128,113,200
April 11, 2025745,3003,043,332,300
April 14, 2025745,3003,089,119,600
April 15, 2025745,3002,948,586,700
April 16, 20251,028,2004,187,218,100
April 17, 20251,028,2004,303,415,100
April 18, 20251,028,2004,291,200,900
April 21, 20251,028,2004,286,217,800
April 22, 20251,028,2004,368,889,900
April 23, 2025185,200787,743,000
Total
—
11,823,50049,977,956,800
Aggregate shares repurchased as of the end of this reporting month
23,367,10099,955,865,500
Progress of share repurchase (%)
81.99
99.96
(Notes) 1. The period of repurchase is based on a trade date, while the date of repurchase is based on the settlement date.
2. It was resolved at the above meeting of the Board of Directors that the method of acquisition shall be open-market repurchase through a trust bank.
3. The acquisition of shares based on the above resolution of the Board of Directors was completed on April 23, 2025 (settlement date basis).



2.Status of disposition
As of April 30, 2025

Number of shares disposed
in the reporting month (shares)
Total amount of
disposition (JPY)
Treasury shares disposed through offering
(Date)
—
—
—
Subtotal
—
—
—
Treasury shares canceled
(Date)
—
—
—
Subtotal
—
—
—
Treasury shares transferred upon merger, share exchange or company split
(Date)
—
—
—
Subtotal
—
—
—
Other (upon exercise of stock options)
(Date)
April 7, 2025
12,100
45,072,500
Subtotal
—
12,100
45,072,500
Total
12,100
45,072,500

3.Status of treasury shares held
As of April 30, 2025
Status of treasury shares held
as of the end of the reporting month
Number of shares (shares)
Total number of issued shares
1,590,961,709
Number of treasury shares held
23,558,061
(Notes) 1. The number of treasury shares held includes shares purchased on a demand for purchase made by shareholders holding shares less than one unit.
2. The number of treasury shares held does not include the shares held by the ESOP trust account and the shares held by the BIP trust account.